Using navigators to deliver electronic patient-reported outcomes for cancer patients
Evaluating the Implementation and Impact of Navigator-delivered ePRO Home Symptom Monitoring and Management
NA · University of Alabama at Birmingham · NCT04809740
This study is testing whether using navigators to help cancer patients report their symptoms electronically during chemotherapy can improve their care and outcomes.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 7500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Alabama at Birmingham (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 2 sites (Birmingham, Alabama and 1 other locations) |
| Trial ID | NCT04809740 on ClinicalTrials.gov |
What this trial studies
This study evaluates the implementation of a navigator-delivered electronic patient-reported outcomes (ePRO) system for cancer patients receiving chemotherapy across multiple practice sites. It aims to identify barriers and facilitators to the implementation of this system and assess its impact on clinical outcomes and healthcare utilization. The study will leverage existing infrastructure from Medicare's payment reform projects to support the delivery of ePROs, focusing on improving outcomes for vulnerable populations. The research will utilize a hybrid design to test the effectiveness of these implementation strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adult cancer patients aged 18 and older who are receiving chemotherapy, targeted therapy, or immunotherapy at the participating institutions.
Not a fit: Patients who are only seeking a second opinion at the participating institution will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the quality of life and overall survival of cancer patients by improving symptom monitoring and healthcare utilization.
How similar studies have performed: Previous studies have shown success with similar electronic home-based patient-reported outcomes interventions, indicating potential for effective implementation in real-world settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patient Group: * Age ≥18 * Cancer patients at participating institution * Receipt of chemotherapy, targeted therapy, and immunotherapy at participating institution from 2019-2026. Exclusion Criteria: - Second opinion only at participating institution.
Where this trial is running
Birmingham, Alabama and 1 other locations
- University of Alabama at Birmingham — Birmingham, Alabama, United States (RECRUITING)
- University of Alabama at Birmingham — Birmingham, Alabama, United States (RECRUITING)
Study contacts
- Study coordinator: Stacey A Ingram, MEd
- Email: saadewakun@uabmc.edu
- Phone: 205-934-6287
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer